This multipotent molecule was specifically developed to combine the anti-cholinergic activity of donepezil, as an AChE inhibitor widely used in AD therapy, with a propargylamine moiety derived from selective MAO B inhibitor, PF9601N (Figure 7) with neuroprotective properties (Bolea et al., 2011). The gene discussed is MAOB; the disease is Alzheimer disease.